Population pharmacokinetics of fluconazole in critically ill patients receiving extracorporeal membrane oxygenation and continuous renal replacement therapy: an ASAP ECMO study
- 10 January 2024
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 68 (1) , e0120123
Abstract
This multicenter study describes the population pharmacokinetics (PK) of fluconazole in critically ill patients receiving concomitant extracorporeal membrane oxygenation (ECMO) and continuous renal replacement therapy (CRRT) and includes an evaluation of different fluconazole dosing regimens for achievement of target exposure associated with maximal efficacy. Serial blood samples were obtained from critically ill patients on ECMO and CRRT receiving fluconazole. Total fluconazole concentrations were measured in plasma using a validated chromatographic assay. A population PK model was developed and Monte Carlo dosing simulations were performed using Pmetrics in R. The probability of target attainment (PTA) of various dosing regimens to achieve fluconazole area under the curve to minimal inhibitory concentration ratio (AUC 0-24 /MIC) >100 was estimated. Eight critically ill patients receiving concomitant ECMO and CRRT were included. A two-compartment model including total body weight as a covariate on clearance adequately described the data. The mean (±standard deviation, SD) clearance and volume of distribution were 2.87 ± 0.63 L/h and 15.90 ± 13.29 L, respectively. Dosing simulations showed that current guidelines (initial loading dose of 12 mg/kg then 6 mg/kg q24h) achieved >90% of PTA for a MIC up to 1 mg/L. None of the tested dosing regimens achieved 90% of PTA for MIC above 2 mg/L. Current fluconazole dosing regimen guidelines achieved >90% PTA only for Candida species with MIC <1 mg/L and thus should be only used for Candida-documented infections in critically ill patients receiving concomitant ECMO and CRRT. Total body weight should be considered for fluconazole dose.Keywords
Funding Information
- The Prince Charles Hospital Research Foundation; ANZIC Foundation; ANZ College of Anaesthetists
- SHPA; NHMRC Australia
This publication has 36 references indexed in Scilit:
- Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutionsThe Lancet Infectious Diseases, 2014
- DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current -Lactam Antibiotic Doses Sufficient for Critically Ill Patients?Clinical Infectious Diseases, 2014
- ASAP ECMO: Antibiotic, Sedative and Analgesic Pharmacokinetics during Extracorporeal Membrane Oxygenation: a multi-centre study to optimise drug therapy during ECMOBMC Anesthesiology, 2012
- Pharmacokinetics and Safety of Fluconazole in Young Infants Supported With Extracorporeal Membrane OxygenationThe Pediatric Infectious Disease Journal, 2012
- Accurate Detection of Outliers and Subpopulations With Pmetrics, a Nonparametric and Parametric Pharmacometric Modeling and Simulation Package for RTherapeutic Drug Monitoring, 2012
- Using pharmacokinetics and pharmacodynamics to optimise dosing of antifungal agents in critically ill patients: a systematic reviewInternational Journal of Antimicrobial Agents, 2012
- Population Pharmacokinetics of Fluconazole in Critically Ill Patients Receiving Continuous Venovenous Hemodiafiltration: Using Monte Carlo Simulations To Predict Doses for Specified Pharmacodynamic TargetsAntimicrobial Agents and Chemotherapy, 2011
- Infections occurring during extracorporeal membrane oxygenation use in adult patientsThe Journal of Thoracic and Cardiovascular Surgery, 2010
- Fluconazole MIC and the Fluconazole Dose/MIC Ratio Correlate with Therapeutic Response among Patients with CandidemiaAntimicrobial Agents and Chemotherapy, 2005
- Safety, Plasma Concentrations, and Efficacy of High-Dose Fluconazole in Invasive Mold InfectionsThe Journal of Infectious Diseases, 1995